Peptide Lab HQ Research Guide
Tirzepatide
A research-focused compound profile covering Tirzepatide identity, dual GIP / GLP-1 receptor agonist research, incretin pathway signaling, glucose metabolism, appetite and satiety research, body-weight research context, concentration reference, reconstitution reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | Tirzepatide |
|---|---|
| Common Research Names | Tirzepatide, LY3298176, dual GIP / GLP-1 receptor agonist, Mounjaro active ingredient, Zepbound active ingredient |
| Compound Type | Modified incretin peptide / dual GIP receptor and GLP-1 receptor agonist research compound |
| CAS Number | Commonly listed as 2023788-19-2; verify against supplier COA |
| PubChem CID | 156588324 |
| Receptor Targets | Glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor |
| Structural Context | GIP-sequence-based peptide containing Aib substitutions at positions 2 and 13, C-terminal amidation, and a Lys20 linker-attached C20 fatty diacid moiety for extended activity. |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈; verify against supplier COA |
| Molecular Weight | Approximately 4813.53 Da; verify against supplier COA |
| Research Category | GIP receptor signaling, GLP-1 receptor signaling, incretin pathway research, glucose metabolism, appetite signaling, gastric-emptying research, body-weight research, and cardiometabolic-marker research |
| Research Context | Commonly discussed in controlled research involving glucose-dependent insulin secretion, glucagon suppression, appetite regulation, satiety response, delayed gastric emptying, body-weight change, glycemic markers, and metabolic pathway documentation. |
| Appearance | White to off-white lyophilized powder, depending on supplier documentation |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
Tirzepatide is commonly discussed in controlled research models involving GIP receptor signaling, GLP-1 receptor signaling, incretin pathway activity, glucose metabolism, insulin and glucagon regulation, appetite signaling, satiety response, gastric-emptying research, body-weight change, and cardiometabolic-marker documentation.
Dual Incretin Receptor Research
Tirzepatide is studied as a dual GIP receptor and GLP-1 receptor agonist, making it distinct from single-pathway GLP-1 receptor agonist research compounds.
Glucose Metabolism Models
Used in research involving glucose-dependent insulin secretion, glucagon regulation, fasting glucose, HbA1c response, and type 2 diabetes study contexts.
Body-Weight Research
Tirzepatide is commonly discussed in obesity and overweight research contexts involving body-weight change, waist circumference, appetite response, and metabolic-marker tracking.
Appetite & Satiety Research
GIP and GLP-1 receptor pathway activity is commonly studied in relation to appetite regulation, reduced calorie intake, satiety signaling, and food-intake behavior.
Gastric Emptying Context
Tirzepatide research commonly includes delayed gastric emptying, gastrointestinal tolerability, absorption timing, and digestive-response marker considerations.
Cardiometabolic Research
Research contexts include body weight, glucose markers, insulin sensitivity, lipid markers, blood pressure, cardiovascular-risk context, and metabolic syndrome-related observations.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on compound form, purity, receptor expression, model type, dose-escalation design, metabolic status, route, timing, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Select Reference Vial
Select a vial size to update the concentration, U-100 unit references, and frequency table below.
Quick Reference Summary
| Reference Vial | 5 mg Tirzepatide |
|---|---|
| Primary Solution Volume | 2.0 mL bacteriostatic water |
| Primary Concentration | 2.5 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 2.5 mg/mL, 1 unit equals 0.025 mg / 25 mcg Tirzepatide. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear to slightly hazy depending on concentration and supplier format. Do not shake!
- For higher-concentration preparations, verify that the material is fully dissolved before recording the final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | Tirzepatide, also referenced as LY3298176 | Tirzepatide is commonly discussed as a dual glucose-dependent insulinotropic polypeptide / glucagon-like peptide-1 receptor agonist research compound. |
| Dual-Receptor Research Context | GIP / GLP-1 receptor pathway context | Commonly discussed in receptor-signaling, incretin-pathway, glucose-handling, insulin-response, appetite-response, and metabolic-marker research contexts. |
| Metabolic Research Context | Clinical-study context only | Tirzepatide has been discussed in clinical-study contexts involving glycemic markers, body-weight markers, insulin sensitivity, lipid markers, and cardiometabolic marker observations. These clinical-study contexts are not research-chemical dosing standards. |
| Glucose / Insulin Marker Research | Model-dependent endocrine-marker tracking | Commonly discussed in glucose regulation, insulin secretion, insulin sensitivity, beta-cell response, incretin-response, and metabolic-homeostasis research models. |
| Appetite / Body-Weight Marker Research | Experimental and clinical-marker context | Tirzepatide-related research is often discussed in appetite signaling, food-intake behavior, body-weight marker trends, energy balance, and body-composition model contexts. |
| Lipid / Cardiometabolic Research | Model-dependent metabolic-marker context | Research discussions commonly include lipid markers, triglyceride markers, cardiometabolic endpoints, hepatic-metabolism context, and metabolic-disease model observations. |
| Public Protocol-Style Reference | Microgram-to-milligram reference examples | Public protocol-style references commonly describe Tirzepatide in microgram-to-milligram examples depending on the research model and preparation format. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, clinical-study references, public protocol-style references, wellness protocols, or public dosing pages should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 5 mg | 2.0 mL | 2.5 mg/mL |
| 10 mg | 2.0 mL | 5 mg/mL |
| 15 mg | 3.0 mL | 5 mg/mL |
| 20 mg | 3.0 mL | 6.67 mg/mL |
| 30 mg | 3.0 mL | 10 mg/mL |
| 40 mg | 3.0 mL | 13.33 mg/mL |
| 50 mg | 3.0 mL | 16.67 mg/mL |
| 60 mg | 3.0 mL | 20 mg/mL |
| 80 mg | 3.0 mL | 26.67 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 2.5 mg/mL | U-100 Unit Reference | Approx. References per 5 mg Vial |
|---|---|---|---|
| 0.1 mg / 100 mcg | 0.04 mL | 4 units | 50 |
| 0.25 mg / 250 mcg | 0.10 mL | 10 units | 20 |
| 0.5 mg / 500 mcg | 0.20 mL | 20 units | 10 |
| 1 mg / 1000 mcg | 0.40 mL | 40 units | 5 |
| 2 mg / 2000 mcg | 0.80 mL | 80 units | 2.5 |
| 2.5 mg / 2500 mcg | 1.00 mL | 100 units | 2 |
| 5 mg / 5000 mcg | 2.00 mL | 200 units | 1 |
| 7.5 mg / 7500 mcg | 3.00 mL | 300 units | 0.7 |
| 10 mg / 10000 mcg | 4.00 mL | 400 units | 0.5 |
| 15 mg / 15000 mcg | 6.00 mL | 600 units | 0.3 |
| 20 mg / 20000 mcg | 8.00 mL | 800 units | 0.3 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Low Conversion Reference | Calculation reference only | 0.1 mg reference amount | 4 units / 0.04 mL |
| Lower Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.25 mg reference amount | 10 units / 0.10 mL |
| Low-to-Mid Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.5 mg reference amount | 20 units / 0.20 mL |
| Standard Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 1 mg reference amount | 40 units / 0.40 mL |
| Mid-Range Conversion Example | Calculation reference only | 2 mg reference amount | 80 units / 0.80 mL |
| Upper Conversion Example | Calculation reference only | 2.5 mg reference amount | 100 units / 1.00 mL |
| 5 mg Preparation Reference | Preparation-level calculation reference | 5 mg reference amount | 200 units / 2.00 mL |
| 7.5 mg Preparation Reference | Preparation-level calculation reference | 7.5 mg reference amount | 300 units / 3.00 mL |
| 10 mg Preparation Reference | Preparation-level calculation reference | 10 mg reference amount | 400 units / 4.00 mL |
| 15 mg Preparation Reference | Preparation-level calculation reference | 15 mg reference amount | 600 units / 6.00 mL |
| 20 mg Preparation Reference | Preparation-level calculation reference | 20 mg reference amount | 800 units / 8.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Receptor Observation Window | 24–72 hours | May be used for GIP / GLP-1 receptor signaling, incretin-pathway response, intracellular signaling, beta-cell marker, or glucose-handling pathway documentation depending on the model. |
| Acute Metabolic Observation Window | Single session to several days | Used for short-term glucose, insulin, appetite-response, endocrine-marker, receptor-response, or early pathway tracking depending on the research design. |
| Short Research Window | 1–4 weeks | May be used for early controlled observation involving glucose-handling markers, appetite-response markers, metabolic markers, or dose-ranging model documentation. |
| Standard Protocol-Style Window | 4–12 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 12–24 weeks or longer | Used when longer documentation is needed for body-weight, glycemic-marker, appetite-response, insulin-sensitivity, lipid-marker, cardiometabolic, or follow-up marker tracking. |
| Follow-Up / Washout | 4–12 weeks | Used to document post-study observations, marker return, delayed response patterns, or return-to-baseline data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. Tirzepatide, also referenced as LY3298176, is commonly discussed in dual GIP / GLP-1 receptor, incretin-pathway, glucose-handling, insulin-response, appetite-response, glycemic-marker, body-weight, lipid-marker, insulin-sensitivity, cardiometabolic, and metabolic-disease research contexts. The selector above updates calculations for 5 mg and 10 mg vial references reconstituted with 2.0 mL bacteriostatic water, and 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 80 mg vial references reconstituted with 3.0 mL bacteriostatic water. Published study references, clinical-study contexts, and public protocol-style frequency references are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
Tirzepatide is commonly discussed in research involving dual GIP / GLP-1 receptor activity, glucose-dependent insulin secretion, glucagon regulation, appetite signaling, delayed gastric emptying, body-weight change, HbA1c response, and cardiometabolic-marker tracking.
Study Limitations
Tirzepatide research includes prescription-product studies, metabolic disease research, obesity studies, type 2 diabetes research, and obstructive sleep apnea with obesity contexts. Findings should be interpreted according to compound form, route, dose-escalation design, study population, metabolic status, and endpoint selection.
Safety Considerations
Research discussion should account for gastrointestinal response, nausea, vomiting, diarrhea, constipation, delayed gastric emptying, pancreatitis context, gallbladder disease, dehydration-related kidney injury, hypoglycemia risk in diabetes contexts, diabetic retinopathy complications, heart-rate observations, thyroid C-cell tumor warning context, peptide purity, sterility documentation, storage conditions, and qualified laboratory handling procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.